Ambarish Pandey1, Kershaw V Patel1, Wanpen Vongpatanasin1, Colby Ayers1, Jarett D Berry1, Robert J Mentz2, Michael J Blaha3, John W McEvoy3,4, Paul Muntner5, Muthiah Vaduganathan6, Adolfo Correa7, Javed Butler7, Daichi Shimbo8, Vijay Nambi9, Christopher deFilippi10, Stephen L Seliger11, Christie M Ballantyne12, Elizabeth Selvin13, James A de Lemos1, Parag H Joshi1. 1. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (A.P., K.V.P., W.V., C.A., J.D.B. J.A.d.L., P.H.J). 2. Division of Cardiology, Duke Clinical Research Institute, Durham, NC (R.J.M.). 3. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, MD (M.J.B., J.W.M.). 4. National Institute for Preventive Cardiology and National University of Ireland, Galway (J.W.M.). 5. Department of Epidemiology, School of Public Health, University of Alabama at Birmingham (P.M.). 6. Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (M.V.). 7. Department of Medicine, University of Mississippi Medical Center, Jackson (A.C., J.B.). 8. Department of Medicine, Columbia University, New York, NY (D.S.). 9. Michael E DeBakey Veterans Affairs hospital and Department of Medicine, Baylor College of Medicine, Houston, TX (V.N.). 10. Inova Heart and Vascular Institute, Falls Church, VA (C.dF.). 11. Division of Nephrology, University of Maryland School of Medicine, Baltimore (S.L.S.). 12. Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.). 13. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore (E.S.).
Abstract
BACKGROUND: Risk for atherosclerotic cardiovascular disease was a novel consideration for antihypertensive medication initiation in the 2017 American College of Cardiology/American Heart Association Blood Pressure (BP) guideline. Whether biomarkers of chronic myocardial injury (high-sensitivity cardiac troponin T ≥6 ng/L] and stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥100 pg/mL) can inform cardiovascular (CV) risk stratification and treatment decisions among adults with elevated BP and hypertension is unclear. METHODS: Participant-level data from 3 cohort studies (Atherosclerosis Risk in Communities Study, Dallas Heart Study, and Multiethnic Study of Atherosclerosis) were pooled, excluding individuals with prevalent CV disease and those taking antihypertensive medication at baseline. Participants were analyzed according to BP treatment group from the 2017 American College of Cardiology/American Heart Association BP guideline and those with high BP (120 to 159/<100 mm Hg) were further stratified by biomarker status. Cumulative incidence rates for CV event (atherosclerotic cardiovascular disease or heart failure), and the corresponding 10-year number needed to treat to prevent 1 event with intensive BP lowering (to target systolic BP <120 mm Hg), were estimated for BP and biomarker-based subgroups. RESULTS: The study included 12 987 participants (mean age, 55 years; 55% women; 21.5% with elevated high-sensitivity cardiac troponin T; 17.7% with elevated NT-proBNP) with 825 incident CV events over 10-year follow-up. Participants with elevated BP or hypertension not recommended for antihypertensive medication with versus without either elevated high-sensitivity cardiac troponin T or NT-proBNP had a 10-year CV incidence rate of 11.0% and 4.6%, with a 10-year number needed to treat to prevent 1 event for intensive BP lowering of 36 and 85, respectively. Among participants with stage 1 or stage 2 hypertension recommended for antihypertensive medication with BP <160/100 mm Hg, those with versus without an elevated biomarker had a 10-year CV incidence rate of 15.1% and 7.9%, with a 10-year number needed to treat to prevent 1 event of 26 and 49, respectively. CONCLUSIONS: Elevations in high-sensitivity cardiac troponin T or NT-proBNP identify individuals with elevated BP or hypertension not currently recommended for antihypertensive medication who are at high risk for CV events. The presence of nonelevated biomarkers, even in the setting of stage 1 or stage 2 hypertension, was associated with lower risk. Incorporation of biomarkers into risk assessment algorithms may lead to more appropriate matching of intensive BP control with patient risk.
BACKGROUND: Risk for atherosclerotic cardiovascular disease was a novel consideration for antihypertensive medication initiation in the 2017 American College of Cardiology/American Heart Association Blood Pressure (BP) guideline. Whether biomarkers of chronic myocardial injury (high-sensitivity cardiac troponin T ≥6 ng/L] and stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥100 pg/mL) can inform cardiovascular (CV) risk stratification and treatment decisions among adults with elevated BP and hypertension is unclear. METHODS: Participant-level data from 3 cohort studies (Atherosclerosis Risk in Communities Study, Dallas Heart Study, and Multiethnic Study of Atherosclerosis) were pooled, excluding individuals with prevalent CV disease and those taking antihypertensive medication at baseline. Participants were analyzed according to BP treatment group from the 2017 American College of Cardiology/American Heart Association BP guideline and those with high BP (120 to 159/<100 mm Hg) were further stratified by biomarker status. Cumulative incidence rates for CV event (atherosclerotic cardiovascular disease or heart failure), and the corresponding 10-year number needed to treat to prevent 1 event with intensive BP lowering (to target systolic BP <120 mm Hg), were estimated for BP and biomarker-based subgroups. RESULTS: The study included 12 987 participants (mean age, 55 years; 55% women; 21.5% with elevated high-sensitivity cardiac troponin T; 17.7% with elevated NT-proBNP) with 825 incident CV events over 10-year follow-up. Participants with elevated BP or hypertension not recommended for antihypertensive medication with versus without either elevated high-sensitivity cardiac troponin T or NT-proBNP had a 10-year CV incidence rate of 11.0% and 4.6%, with a 10-year number needed to treat to prevent 1 event for intensive BP lowering of 36 and 85, respectively. Among participants with stage 1 or stage 2 hypertension recommended for antihypertensive medication with BP <160/100 mm Hg, those with versus without an elevated biomarker had a 10-year CV incidence rate of 15.1% and 7.9%, with a 10-year number needed to treat to prevent 1 event of 26 and 49, respectively. CONCLUSIONS: Elevations in high-sensitivity cardiac troponin T or NT-proBNP identify individuals with elevated BP or hypertension not currently recommended for antihypertensive medication who are at high risk for CV events. The presence of nonelevated biomarkers, even in the setting of stage 1 or stage 2 hypertension, was associated with lower risk. Incorporation of biomarkers into risk assessment algorithms may lead to more appropriate matching of intensive BP control with patient risk.
Authors: Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani Journal: Circulation Date: 2019-03-05 Impact factor: 29.690
Authors: Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983
Authors: Paul Muntner; Robert M Carey; Samuel Gidding; Daniel W Jones; Sandra J Taler; Jackson T Wright; Paul K Whelton Journal: Circulation Date: 2017-11-13 Impact factor: 29.690
Authors: Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz Journal: JAMA Date: 2014-02-05 Impact factor: 56.272
Authors: James A de Lemos; Mark H Drazner; Torbjorn Omland; Colby R Ayers; Amit Khera; Anand Rohatgi; Ibrahim Hashim; Jarett D Berry; Sandeep R Das; David A Morrow; Darren K McGuire Journal: JAMA Date: 2010-12-08 Impact factor: 56.272
Authors: Ronald G Victor; Robert W Haley; DuWayne L Willett; Ronald M Peshock; Patrice C Vaeth; David Leonard; Mujeeb Basit; Richard S Cooper; Vincent G Iannacchione; Wendy A Visscher; Jennifer M Staab; Helen H Hobbs Journal: Am J Cardiol Date: 2004-06-15 Impact factor: 2.778
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245
Authors: Yuichiro Yano; Michael Griswold; Wanmei Wang; Philip Greenland; Donald M Lloyd-Jones; Gerardo Heiss; Rebecca F Gottesman; Thomas H Mosley Journal: J Am Heart Assoc Date: 2018-08-07 Impact factor: 5.501
Authors: Nicholas A Marston; Marc P Bonaca; Petr Jarolim; Erica L Goodrich; Deepak L Bhatt; Philippe G Steg; Marc Cohen; Robert F Storey; Per Johanson; Stephen D Wiviott; Eugene Braunwald; Marc S Sabatine; David A Morrow Journal: JAMA Cardiol Date: 2020-11-01 Impact factor: 14.676
Authors: Aliza Hussain; Wensheng Sun; Anita Deswal; James A de Lemos; John W McEvoy; Ron C Hoogeveen; Kunihiro Matsushita; David Aguilar; Biykem Bozkurt; Salim S Virani; Amil M Shah; Elizabeth Selvin; Chiadi Ndumule; Christie M Ballantyne; Vijay Nambi Journal: J Am Coll Cardiol Date: 2021-02-09 Impact factor: 24.094
Authors: Elliot J Stein; William F Fearon; Sammy Elmariah; Juyong B Kim; Samir Kapadia; Dharam J Kumbhani; Linda Gillam; Brian Whisenant; Nishath Quader; Alan Zajarias; Frederick G Welt; Anthony A Bavry; Megan Coylewright; Robert N Piana; Ravinder R Mallugari; Daniel E Clark; Jay N Patel; Holly Gonzales; Deepak K Gupta; Anna Vatterott; Natalie Jackson; Shi Huang; Brian R Lindman Journal: J Am Heart Assoc Date: 2022-03-18 Impact factor: 6.106
Authors: Simon B Ascher; Rebecca Scherzer; Jame A de Lemos; Michelle M Estrella; Vasantha K Jotwani; Pranav S Garimella; Alexander L Bullen; Walter T Ambrosius; Christie M Ballantyne; Vijay Nambi; Anthony A Killeen; Joachim H Ix; Michael G Shlipak; Jarett D Berry Journal: J Am Heart Assoc Date: 2022-03-04 Impact factor: 6.106
Authors: Neela D Thangada; Kershaw V Patel; Bradley Peden; Vijay Agusala; Julia Kozlitina; Sonia Garg; Mark H Drazner; Colby Ayers; Jarett D Berry; Ambarish Pandey Journal: J Am Heart Assoc Date: 2021-02-22 Impact factor: 5.501